152 related articles for article (PubMed ID: 27056836)
41. Multiple Genomic Events Altering Hominin SIGLEC Biology and Innate Immunity Predated the Common Ancestor of Humans and Archaic Hominins.
Khan N; de Manuel M; Peyregne S; Do R; Prufer K; Marques-Bonet T; Varki N; Gagneux P; Varki A
Genome Biol Evol; 2020 Jul; 12(7):1040-1050. PubMed ID: 32556248
[TBL] [Abstract][Full Text] [Related]
42. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.
Yu Q; König R; Pillai S; Chiles K; Kearney M; Palmer S; Richman D; Coffin JM; Landau NR
Nat Struct Mol Biol; 2004 May; 11(5):435-42. PubMed ID: 15098018
[TBL] [Abstract][Full Text] [Related]
43. Strand-biased cytosine deamination at the replication fork causes cytosine to thymine mutations in Escherichia coli.
Bhagwat AS; Hao W; Townes JP; Lee H; Tang H; Foster PL
Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2176-81. PubMed ID: 26839411
[TBL] [Abstract][Full Text] [Related]
44. Generation of Genomic Alteration from Cytidine Deamination.
Liu X; Meng FL
Adv Exp Med Biol; 2018; 1044():49-64. PubMed ID: 29956291
[TBL] [Abstract][Full Text] [Related]
45. HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action.
Santa-Marta M; Aires da Silva F; Fonseca AM; Rato S; Goncalves J
Mol Immunol; 2007 Jan; 44(4):583-90. PubMed ID: 16580072
[TBL] [Abstract][Full Text] [Related]
46. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
47. Chromosomal Rearrangements as Barriers to Genetic Homogenization between Archaic and Modern Humans.
Rogers RL
Mol Biol Evol; 2015 Dec; 32(12):3064-78. PubMed ID: 26399483
[TBL] [Abstract][Full Text] [Related]
48. Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors.
Russell RA; Wiegand HL; Moore MD; Schäfer A; McClure MO; Cullen BR
J Virol; 2005 Jul; 79(14):8724-31. PubMed ID: 15994766
[TBL] [Abstract][Full Text] [Related]
49. APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz.
Covino DA; Purificato C; Catapano L; Galluzzo CM; Gauzzi MC; Vella S; Lefebvre E; Seyedkazemi S; Andreotti M; Fantuzzi L
Front Immunol; 2018; 9():1839. PubMed ID: 30135687
[TBL] [Abstract][Full Text] [Related]
50. APOBEC Enzymes as Targets for Virus and Cancer Therapy.
Olson ME; Harris RS; Harki DA
Cell Chem Biol; 2018 Jan; 25(1):36-49. PubMed ID: 29153851
[TBL] [Abstract][Full Text] [Related]
51. Creative deaminases, self-inflicted damage, and genome evolution.
Conticello SG
Ann N Y Acad Sci; 2012 Sep; 1267():79-85. PubMed ID: 22954220
[TBL] [Abstract][Full Text] [Related]
52. AID/APOBEC deaminases and cancer.
Rebhandl S; Huemer M; Greil R; Geisberger R
Oncoscience; 2015; 2(4):320-33. PubMed ID: 26097867
[TBL] [Abstract][Full Text] [Related]
53. The Enzymatic Activity of APOBE3G Multimers.
Pan Y; Zagorski K; Shlyakhtenko LS; Lyubchenko YL
Sci Rep; 2018 Dec; 8(1):17953. PubMed ID: 30560880
[TBL] [Abstract][Full Text] [Related]
54. HIV-1 restriction by endogenous APOBEC3G in the myeloid cell line THP-1.
Ikeda T; Molan AM; Jarvis MC; Carpenter MA; Salamango DJ; Brown WL; Harris RS
J Gen Virol; 2019 Jul; 100(7):1140-1152. PubMed ID: 31145054
[TBL] [Abstract][Full Text] [Related]
55. An overview of cytidine deaminases.
Navaratnam N; Sarwar R
Int J Hematol; 2006 Apr; 83(3):195-200. PubMed ID: 16720547
[TBL] [Abstract][Full Text] [Related]
56. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
[TBL] [Abstract][Full Text] [Related]
57. Analysis of Mutations and Dysregulated Pathways Unravels Carcinogenic Effect and Clinical Actionability of Mutational Processes.
Jiang Z; Liao G; Yang Y; Lan Y; Xu L; Yan M; Zhou Y; Zhu J; Liu W; Bai J; Xiao Y; Li X
Front Cell Dev Biol; 2021; 9():768981. PubMed ID: 34901014
[TBL] [Abstract][Full Text] [Related]
58. Identification of a signature of evolutionarily conserved stress-induced mutagenesis in cancer.
Cisneros LH; Vaske C; Bussey KJ
Front Genet; 2022; 13():932763. PubMed ID: 36147501
[TBL] [Abstract][Full Text] [Related]
59. Genes that are Used Together are More Likely to be Fused Together in Evolution by Mutational Mechanisms: A Bioinformatic Test of the Used-Fused Hypothesis.
Bolotin E; Melamed D; Livnat A
Evol Biol; 2023; 50(1):30-55. PubMed ID: 36816837
[TBL] [Abstract][Full Text] [Related]
60. The in vitro Biochemical Characterization of an HIV-1 Restriction Factor APOBEC3F: Importance of Loop 7 on Both CD1 and CD2 for DNA Binding and Deamination.
Chen Q; Xiao X; Wolfe A; Chen XS
J Mol Biol; 2016 Jul; 428(13):2661-70. PubMed ID: 27063502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
